Alumis Inc. will present the 24‑week topline results from its Phase 3 ONWARD program at a late‑breaking oral presentation on March 28, 2026, at 11:12 a.m. MDT in Bellco Theatre 3 during the American Academy of Dermatology Annual Meeting in Denver, Colorado.
The ONWARD program evaluates envudeucitinib, a next‑generation oral TYK2 inhibitor, in moderate‑to‑severe plaque psoriasis. The presentation will cover data from the randomized, double‑blind, active‑comparator‑ and placebo‑controlled ONWARD 1 and ONWARD 2 studies, and a biomarker analysis from the Phase 2 STRIDE trial will be shown as an e‑poster at the same meeting.
This presentation marks a critical milestone for Alumis’s clinical and commercial prospects. Envudeucitinib’s selective inhibition of TYK2 targets IL‑23, IL‑17, and type I interferon pathways, offering an oral alternative to biologic therapies. Positive topline data announced on January 6, 2026, showed the drug met all primary and secondary endpoints with high statistical significance and superior skin clearance versus placebo and apremilast.
Alumis is also exploring envudeucitinib for systemic lupus erythematosus and has other pipeline candidates, including A‑005 for neuroinflammatory diseases and lonigutamab for thyroid eye disease. The company recently completed an upsized public offering, strengthening its balance sheet for continued development.
An investor webcast will be hosted on March 29, 2026, at 5:00 p.m. MDT to review the Phase 3 data presented at AAD, giving investors an opportunity to discuss the implications for future development and regulatory strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.